DSIP: Delta Sleep-Inducing Peptide Research Overview

DSIP was identified by Schoenenberger and Monnier in 1977 through fractionation of cerebral venous blood from rabbits during electrical stimulation that produced sleep-like EEG patterns. The peptide was identified as a fraction with reproducible sleep-promoting activity in animal models.^[1]

The sequence (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) was characterized and the synthetic peptide synthesized for further research. DSIP has been studied across many preclinical pharmacology research areas in the decades since, though the exact receptor and signaling mechanism remain incompletely characterized — making the compound an ongoing area of investigation.^[2]

DSIP is studied as a research reference compound in preclinical neuropharmacology research. It has not been approved by the FDA for any human therapeutic or medical purpose.

DSIP structural features:

• Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (9 residues)

• Length: 9 amino acids (nonapeptide)

• Molecular formula: C₃₅H₄₈N₁₀O₁₅

• Molecular weight: approximately 848.83 Da

• N-terminal: free amine (no acetylation)

• C-terminal: free acid (no amidation)

DSIP's sequence is notable for containing multiple glycine residues (positions 3, 4, 8) which provide backbone flexibility. The acidic residues (Asp, Glu) give the peptide a net negative charge at physiological pH. The N-terminal tryptophan is a defining feature of the compound.^[3]

DSIP's receptor pharmacology remains incompletely characterized in research literature.

Despite decades of research, the specific receptor (or receptors) that mediate DSIP signaling have not been definitively identified. This places DSIP in an unusual category of research peptides — those with well-characterized behavioral effects in animal models but uncertain molecular targets.^[4]

Research has explored several candidate receptor interactions including effects at the GABA system, opioid receptors, and various neuropeptide receptors. None has emerged as a definitive primary target. The lack of receptor clarity has limited progress in DSIP pharmacology relative to peptides with well-defined receptor pharmacology.^[5]

DSIP's original characterization as a delta-EEG-associated peptide motivated continued research on cortical electrophysiology and sleep architecture. Animal models with EEG monitoring have been the primary substrate for this research line.^[1][2]

DSIP research has explored several preclinical domains over the decades since its identification.

Rodent EEG studies examining DSIP effects on sleep stage distribution have been conducted across multiple research groups. Endpoints include time in slow-wave sleep, REM sleep, and total sleep time.^[2]

Animal models of stress have examined DSIP effects on stress hormone responses and behavioral stress markers.^[6]

DSIP serves as a tool compound in studies of less well-characterized neuropeptide signaling. The lack of identified receptor makes it interesting as a research substrate for investigations of orphan signaling mechanisms.^[4]

DSIP is a relatively small unmodified peptide. Standard handling applies.

Lyophilized DSIP is stored at minus 20 degrees Celsius for long-term preservation.

Bacteriostatic water or sterile water are standard reconstitution solvents.

HPLC for purity, mass spectrometry for identity confirmation, and endotoxin screening. Each batch of Instant Peptides DSIP ships with a full Certificate of Analysis.

Instant Peptides supplies DSIP as a synthetic lyophilized reference compound. Material is supplied to qualified research professionals. Not for human or animal consumption.

View the product page for current pricing and the Certificate of Analysis for the active batch.